# PACIFIC 6 (NCT03693300)

> A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03693300
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Non-small Cell Lung Cancer (NSCLC)
- Interventions: Durvalumab
- Enrollment: 117
- Primary outcome: Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 20
- Podcasts: 10
- YouTube: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pacific-6-nct03693300

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03693300", "email": "<work email>"}; the inbox owner confirms by the emailed link.